|
1) Eustatia-Rutten CF, Corssmit EP, Heemstra KA, et al. Autonomic nervous system function in chronic exogenous subclinical thyrotoxicosis and the effect of restoring euthyroidism. J Clin Endocrinol Metab. 2008; 93: 2835-41
|
|
|
|
2) Smit JW, Eustatia-Rutten CF, Corssmit EP, et al. Reversible diastolic dysfunction after long-term exogenous subclinical hyperthyroidism: a randomized, placebo-controlled study. J Clin Endocrinol Metab. 2005; 90: 6041-7
|
|
|
|
|
|
3) Ertugrul DT, Gursoy A, Sahin M, et al. Evaluation of brain natriuretic peptide levels in hyper-thyroidism and hypothyroidism. J Natl Med Assoc. 2008; 100: 401-5
|
|
|
|
|
|
4) Iqbal A, Schirmer H, Lunde P, et al. Thyroid stimulating hormone and left ventricular func-tion. J Clin Endocrinol Metab. 2007; 92: 3504-10
|
|
|
|
|
|
5) Takashima N, Niwa Y, Mannami T, et al. Characterization of subclinical thyroid dysfunc-tion from cardiovascular and metabolic viewpoints: the Suita study. Circ J. 2007; 71: 191-5
|
|
|
|
|
6) Belaya ZE, Melnichenko GA, Rozhinskaya LY, et al. Subclinical hyperthyroidism of variable etiology and its influence on bone in postmeno-pausal women. Hormones (Athens). 2007; 6: 62-70
|
|
|
|
|
|
7) Buscemi S, Verga S, Cottone S, et al. Favorable clinical heart and bone effects of anti-thyroid drug therapy in endogenous subclinical hyper-thyroidism. J Endocrinol Invest. 2007; 30: 230-5
|
|
|
|
|
|
8) Morris MS. The association between serum thyroid-stimulating hormone in its reference range and bone status in postmenopausal American women. Bone. 2007; 40: 1128-34
|
|
|
|
|
|
9) Abe E, Sun L, Mechanick J, et al. Bone loss in thyroid disease: role of low TSH and high thyroid hormone. Ann N Y Acad Sci. 2007; 1116: 383-91
|
|
|
|
|
|
10) Haentjens P, Van Meerhaeghe A, Poppe K, et al. Subclinical thyroid dysfunction and mortality: An estimate of relative and absolute excess all-cause mortality based on time-to-event data from cohort studies. Eur J Endocrinol. 2008; 159: 329-41
|
|
|
|
|
|
11) Surks MI, Ortiz E, Daniels GH, et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA. 2004; 291: 228-38
|
|
|
|
|
|
12) Psaltopoulou T, Ilias I, Toumanidis S, et al. Endogenous subclinical hyperthyroidism: Metabolic and cardiac parameters. Eur J Intern Med. 2007; 18: 423-9
|
|
|
|
|
|
13) Cooper DS. Approach to the patient with subclinical hyperthyroidism. J Clin Endocrinol Metab. 2007; 92: 3-9
|
|
|
|
|
|
14) Razvi S, Shakoor A, Vanderpump M, et al. The influence of age on the relationship between subclinical hypothyroidism and ischemic heart disease: a meta-analysis. J Clin Endocrinol Metab. 2008; 93: 2998-3007
|
|
|
|
|
|
15) Mariotti S, Cambuli VM. Cardiovascular risk in elderly hypothyroid patients. Thyroid. 2007; 17: 1067-73
|
|
|
|
|
|
16) Ochs N, Auer R, Bauer DC, et al. Meta-analysis: subclinical thyroid dysfunction and the risk for coronary heart disease and mortality. Ann Intern Med. 2008; 148: 832-45
|
|
|
|
|
|
17) Baycan S, Erdogan D, Caliskan M, et al. Coronary flow reserve is impaired in subclinical hypothyroidism. Clin Cardiol. 2007; 30: 562-6
|
|
|
|
|
|
18) Oflaz H, Kurt R, Sen F, et al. Coronary flow reserve after L: -thyroxine therapy in Hashimoto's thyroiditis patients with subclinical and overt hypothyroidism. Endocrine. 2007; 32: 264-70
|
|
|
|
|
|
19) Dardano A, Ghiadoni L, Plantinga Y, et al. Recombinant human thyrotropin reduces endothelium-dependent vasodilation in patients monitored for differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2006; 91: 4175-8
|
|
|
|
|
|
20) Nagasaki T, Inaba M, Kumeda Y, et al. Increased pulse wave velocity in subclinical hypothyroid-ism. J Clin Endocrinol Metab. 2006; 91: 154-8
|
|
|
|
|
|
21) Nagasaki T, Inaba M, Yamada S, et al. Changes in brachial-ankle pulse wave velocity in sub-clinical hypothyroidism during normalization of thyroid function. Biomed Pharmacother. 2007; 61: 482-7
|
|
|
|
|
|
22) Franzoni F, Galetta F, Fallahi P, et al. Carotid integrated backscatter analysis in patients with subclinical hypothyroidism. Clin Endocrinol (Oxf). 2008; 68: 278-83
|
|
|
|
|
|
23) Squizzato A, Romualdi E, Piantanida E, et al. Subclinical hypothyroidism and deep venous thrombosis. A pilot cross-sectional study. Thromb Haemost. 2007; 97: 803-6
|
|
|
|
|
|
24) Erdem TY, Ercan M, Ugurlu S, et al. Plasma viscosity, an early cardiovascular risk factor in women with subclinical hypothyroidism. Clin Hemorheol Microcirc. 2008; 38: 219-25
|
|
|
|
|
|
25) Poppe K, Velkeniers B, Glinoer D. The role of thyroid autoimmunity in fertility and pregnancy. Nat Clin Pract Endocrinol Metab. 2008; 4: 394-405
|
|
|
|
|
|
26) Velija-Asimi Z, Karamehic J. The effects of treatment of subclinical hypothyroidism on metabolic control and hyperinsulinemia. Med Arh. 2007; 61: 20-1
|
|
|
|
|
|
27) Chen HS, Wu TE, Jap TS, et al. Subclinical hypothyroidism is a risk factor for nephropathy and cardiovascular diseases in type 2 diabetic patients. Diabet Med. 2007; 24: 1336-44
|
|
|
|
|
|
28) Laukkarinen J, Kiudelis G, Lempinen M, et al. Increased prevalence of subclinical hypo-thyroidism in common bile duct stone patients. J Clin Endocrinol Metab. 2007; 92: 4260-4
|
|
|
|
|
|
29) Karmisholt J, Laurberg P. Serum TSH and serum thyroid peroxidase antibody fluctuate in parallel and high urinary iodine excretion predicts subsequent thyroid failure in a 1-year study of patients with untreated subclinical hypothyroid-ism. Eur J Endocrinol. 2008; 158: 209-15
|
|
|
|
|
|
30) Peeters RP. Thyroid hormones and aging. Hormones (Athens). 2008; 7: 28-35
|
|
|
|
|
|
31) Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction. Endocr Rev. 2008; 29: 76-131
|
|
|
|
|